Do analysts rate TLRY or TLSA?

Tilray Brands currently has a consensus price target of $11.50, suggesting a potential upside of 129.08%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts clearly believe Tilray Brands is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, TLRY or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Tilray Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tilray Brands $821.31M 0.71 -$2.19B -$13.65 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Do analysts rate TLSA or CLYM?

Climb Bio has a consensus target price of $21.64, suggesting a potential upside of 100.34%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Climb Bio 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07

Which has stronger valuation & earnings, TLSA or CLYM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is TLSA or CLYM more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Climb Bio N/A -31.45% -30.39%

Do analysts rate TLSA or ACRS?

Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13

Which has better earnings and valuation, TLSA or ACRS?

Tiziana Life Sciences has higher earnings, but lower revenue than Aclaris Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Aclaris Therapeutics $7.83M 73.13 -$64.92M -$0.56 N/A

Do analysts rate TLSA or GYRE?

Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 185.71%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, TLSA or GYRE?

Gyre Therapeutics has higher revenue and earnings than Tiziana Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Gyre Therapeutics $116.59M 4.95 $5.03M -$0.09 N/A

Do analysts rate ZSQR or TLSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ZSQR or TLSA?

Coeptis Therapeutics has higher revenue and earnings than Tiziana Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coeptis Therapeutics $1.36M 392.91 -$11.92M -$2.52 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Tiziana Life Sciences (TLSA) Competitors

$1.16 -0.06 (-4.92%)

Closing price 04:00 PM Eastern

Extended Trading

$1.14 -0.01 (-1.29%)

As of 07:40 PM Eastern

Compare

TLSA vs. TLRY, CLYM, ACRS, GYRE, and ZSQR

Should you buy Tiziana Life Sciences stock or one of its competitors? MarketBeat compares Tiziana Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tiziana Life Sciences include Tilray Brands (TLRY), Climb Bio (CLYM), Aclaris Therapeutics (ACRS), Gyre Therapeutics (GYRE), and Coeptis Therapeutics (ZSQR). These companies are all part of the "pharmaceutical products" industry.

How does Tiziana Life Sciences compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

9.4% of Tilray Brands shares are held by institutional investors. 0.8% of Tilray Brands shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tilray Brands currently has a consensus price target of $11.50, suggesting a potential upside of 129.08%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts clearly believe Tilray Brands is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tilray Brands has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Tiziana Life Sciences has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tiziana Life Sciences' return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Tilray Brands had 19 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 20 mentions for Tilray Brands and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.87 beat Tilray Brands' score of 0.61 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Tilray Brands	Positive
Tiziana Life Sciences	Very Positive

Tiziana Life Sciences has lower revenue, but higher earnings than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.71	-$2.19B	-$13.65	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Summary

Tilray Brands beats Tiziana Life Sciences on 7 of the 13 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Climb Bio?

Tiziana Life Sciences (NASDAQ:TLSA) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Tiziana Life Sciences has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

69.8% of Climb Bio shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tiziana Life Sciences' return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Climb Bio	N/A	-31.45%	-30.39%

Climb Bio has a consensus target price of $21.64, suggesting a potential upside of 100.34%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

In the previous week, Climb Bio had 6 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 7 mentions for Climb Bio and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.87 beat Climb Bio's score of 0.60 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Climb Bio	Positive

Summary

Tiziana Life Sciences and Climb Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Aclaris Therapeutics?

Tiziana Life Sciences (NASDAQ:TLSA) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Tiziana Life Sciences has higher earnings, but lower revenue than Aclaris Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Aclaris Therapeutics	$7.83M	73.13	-$64.92M	-$0.56	N/A

Tiziana Life Sciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Tiziana Life Sciences' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

In the previous week, Aclaris Therapeutics had 13 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.87 beat Aclaris Therapeutics' score of 1.31 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Aclaris Therapeutics	Positive

Tiziana Life Sciences has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

98.3% of Aclaris Therapeutics shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

Aclaris Therapeutics beats Tiziana Life Sciences on 8 of the 14 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Gyre Therapeutics?

Tiziana Life Sciences (NASDAQ:TLSA) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Tiziana Life Sciences has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Tiziana Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Gyre Therapeutics	$116.59M	4.95	$5.03M	-$0.09	N/A

Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 185.71%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tiziana Life Sciences has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Tiziana Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Gyre Therapeutics	-5.44%	3.13%	2.67%

In the previous week, Tiziana Life Sciences and Tiziana Life Sciences both had 1 articles in the media. Gyre Therapeutics' average media sentiment score of 1.89 beat Tiziana Life Sciences' score of 1.87 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Gyre Therapeutics	Very Positive

24.0% of Gyre Therapeutics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Gyre Therapeutics beats Tiziana Life Sciences on 10 of the 12 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tiziana Life Sciences has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Tiziana Life Sciences' return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.87 beat Coeptis Therapeutics' score of 0.62 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Coeptis Therapeutics	Positive
Tiziana Life Sciences	Very Positive

Coeptis Therapeutics has higher revenue and earnings than Tiziana Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	392.91	-$11.92M	-$2.52	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Coeptis Therapeutics has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Summary

Tiziana Life Sciences beats Coeptis Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Tiziana Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSA vs. The Competition

Export

Metric	Tiziana Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$155.26M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	N/A	18.83	24.65	23.63
Price / Sales	N/A	290.84	500.87	105.21
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	N/A	8.00	10.43	6.70
Net Income	-$18.43M	$23.89M	$3.56B	$337.26M
7 Day Performance	-1.69%	-3.49%	-1.39%	-1.41%
1 Month Performance	-26.58%	1.03%	0.86%	1.15%
1 Year Performance	-15.33%	34.39%	19.42%	22.61%

Tiziana Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSA Tiziana Life Sciences	1.0235 of 5 stars	$1.16 -4.9%	N/A	-14.1%	$155.26M	N/A	N/A	8
TLRY Tilray Brands	3.5401 of 5 stars	$5.26 +4.5%	$11.50 +118.8%	+26.1%	$612.47M	$821.31M	N/A	2,842	Trending News
CLYM Climb Bio	3.7163 of 5 stars	$10.64 -1.2%	$21.64 +103.3%	+731.3%	$608.67M	N/A	N/A	9	Analyst Forecast High Trading Volume
ACRS Aclaris Therapeutics	3.336 of 5 stars	$4.33 -0.8%	$11.50 +165.9%	+188.6%	$605.43M	$7.83M	N/A	100	Positive News
GYRE Gyre Therapeutics	2.5569 of 5 stars	$6.13 +1.3%	$17.00 +177.3%	-27.9%	$594.79M	$116.59M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSA) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. TLRY, CLYM, ACRS, GYRE, and ZSQR

How does Tiziana Life Sciences compare to Tilray Brands?

Summary

How does Tiziana Life Sciences compare to Climb Bio?

Summary

How does Tiziana Life Sciences compare to Aclaris Therapeutics?

Summary

How does Tiziana Life Sciences compare to Gyre Therapeutics?

Summary

How does Tiziana Life Sciences compare to Coeptis Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. TLRY, CLYM, ACRS, GYRE, and ZSQR

How does Tiziana Life Sciences compare to Tilray Brands?

Do insiders & institutionals hold more shares of TLRY or TLSA?

Do analysts rate TLRY or TLSA?

Which has more volatility and risk, TLRY or TLSA?

Is TLRY or TLSA more profitable?

Does the media favor TLRY or TLSA?

Which has better valuation and earnings, TLRY or TLSA?

Summary

How does Tiziana Life Sciences compare to Climb Bio?

Which has more risk & volatility, TLSA or CLYM?

Do institutionals and insiders believe in TLSA or CLYM?

Is TLSA or CLYM more profitable?

Do analysts rate TLSA or CLYM?

Which has stronger valuation & earnings, TLSA or CLYM?

Does the media prefer TLSA or CLYM?

Summary

How does Tiziana Life Sciences compare to Aclaris Therapeutics?

Which has better earnings and valuation, TLSA or ACRS?

Is TLSA or ACRS more profitable?

Does the media prefer TLSA or ACRS?

Which has more risk and volatility, TLSA or ACRS?

Do institutionals & insiders believe in TLSA or ACRS?

Do analysts rate TLSA or ACRS?

Summary

How does Tiziana Life Sciences compare to Gyre Therapeutics?

Which has more volatility and risk, TLSA or GYRE?

Which has stronger earnings & valuation, TLSA or GYRE?

Do analysts rate TLSA or GYRE?

Is TLSA or GYRE more profitable?

Does the media refer more to TLSA or GYRE?

Do insiders & institutionals believe in TLSA or GYRE?

Summary

How does Tiziana Life Sciences compare to Coeptis Therapeutics?

Do analysts rate ZSQR or TLSA?

Is ZSQR or TLSA more profitable?

Does the media prefer ZSQR or TLSA?

Which has preferable earnings and valuation, ZSQR or TLSA?

Do institutionals and insiders have more ownership in ZSQR or TLSA?

Which has more risk & volatility, ZSQR or TLSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools